ArticleBMC neurology2025
Global burden, spatiotemporal disparities, and sex-specific trends of early- and late-onset Alzheimer's disease and other dementias: a comparative analysis and projections to 2035.
Article in BMC neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
introductionEarly-onset Alzheimer's disease and other dementias (EOAD) and late-onset Alzheimer's disease and other dementias (LOAD) represent significant global disease burden challenges. However, previous studies have frequently overlooked differences in their spatial distribution, population characteristics, temporal trends, and healthcare demands. This study aims to systematically compare the burden of EOAD and LOAD at global and regional levels from 1990 to 2021, analyzing disparities in spatial patterns, demographic features, and temporal trajectories, while projecting future trends.
methodsData were extracted from the GBD 2021 database. EOAD was defined as age-standardized cases among individuals aged 40-64 years, and LOAD as those aged ≥ 65 years. Primary outcomes included incidence, mortality, and disability-adjusted life years (DALYs). Analyses covered global, Socio-Demographic Index (SDI) regions, and 21 regions from 1990 to 2021. Bayesian age-period-cohort (BAPC) modeling projected disease burdens to 2035.
resultsIn 2021, LOAD demonstrated a substantially higher global burden than EOAD: incidence cases (8,455,150 [95% UI: 5,818,063-11,461,560] vs. 1,381,906 [894,768-1,963,453]), mortality cases (1,879,291 [471,472-4,968,222] vs. 73,386 [14,059-232,170]), and DALYs (32,558,570 [14,907,368-71,154,572] vs. 3,774,117 [1,696,439-8,881,154]). LOAD exhibited stronger female predominance globally compared to EOAD. From 1990 to 2021, LOAD burden showed an initial decline followed by resurgence, stabilizing overall, while EOAD displayed persistent gradual growth. EOAD had higher annualized percentage changes (AAPC) than LOAD: incidence (0.18% [95% CI: 0.14-0.21] vs. 0.03% [-0.02-0.07]), mortality (0.07% [0.04-0.10] vs. 0.01% [-0.02-0.04]), and DALYs (0.07% [0.05-0.09] vs. 0.03% [-0.00-0.06]). BAPC projections indicated LOAD burden will remain significantly higher than EOAD by 2035. Geographically, East Asia reported the highest absolute burden for both conditions, while Central Sub-Saharan Africa and Tropical Latin America showed peak ASIR, ASMR and AS-DALYs. South Asia exhibited the fastest growth rates.
conclusionEOAD and LOAD demonstrate distinct spatial distributions, sex-specific patterns, and temporal trends. Differentiated strategies targeting these two conditions are urgently needed to achieve precision public health goals.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.